Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
December 2024 Update: There is a significant development concerning eye-related side effects of Ozempic and other semaglutide drugs. Two large medical studies from Denmark presented more evidence of a link between Ozempic and an eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), finding that people who used Ozempic have more than a two-times increased risk of developing this serious eye side effect, which can cause vision loss and blindness.
These two recent studies serve to confirm what was first reported in a July 2024 medical journal article, that Wegovy, Rybelsus, and Ozempic are linked to eye problems because semaglutide, which is the active ingredient for each of these three drugs, is associated with NAION.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many.
Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss.
We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss.
And because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus, those drug injury cases would not be filed against patients’ doctors.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
Ozempic Vision Loss Claims Compensation Payments Made in 2025
Some compensation payments for Ozempic vision loss claims are being made in Europe, according to recent news reports.
From this November 21, 2025, article, “Denmark Compensates Four Over Vision Loss Linked To Ozempic, Wegovy“, published by the Agence France Presse (AFP):
To read more of this article, click below:
Four people in Denmark who developed serious eye conditions after using popular weight-loss and diabetes drugs Wegovy and Ozempic are entitled to compensation, an independent body ruled Friday.
More than 40 people had sought reimbursement after they said they had developed a serious eye condition as a result of using one of the drugs, both made by Novo Nordisk, according to the Danish Patient Compensation association.
The condition — NAION (non-arteritic anterior ischemic optic neuropathy) — is a lack of blood supply to the optic nerve, which can lead to a loss of vision.
The association said that it had ruled on five cases so far, and found four people who merited compensation….
In Denmark, health authorities generally pay out medical compensation for a drug injury such as NAION linked to Ozempic. The Danish Patient Compensation association is an independent body that evaluates these types of patient claims on behalf of the government.
Over the past year, we have heard from people with Ozempic vision loss claims who are seeking compensation payments. In the US, those claims would be filed as drug injury lawsuits in the court system. When successful, the resulting legal compensation payments would be made by the responsible drug company, Novo Nordisk.
Among the liability allegations that would be asserted in the lawsuits for those US Ozempic vision loss claims is Novo Nordisk’s failure to warn that semaglutide has been linked to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) in several medical studies. The current Ozempic drug label in the US does not have any warnings about NAION.
We are investigating Ozempic vision loss claims for patients who have been diagnosed with NAION, as well as similar cases with the use of Wegovy or Rybelsus, which are two other semaglutide-containing drugs from Novo Nordisk.
Again, these drug injury lawsuits with vision loss claims involving Ozempic, Wegovy, and Rybelsus would be filed against Novo Nordisk for its failure to warn about the increased risk of NAION associated with semaglutide in its current US drug labels for those semaglutide-containing drugs.
If you are interested, you can submit an online Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form. Attorney Tom Lamb reviews each one of these submissions. He evaluates them as possible drug injury lawsuits seeking compensation payments for the person suffering from a loss of vision or blindness due to NAION. This case evaluation service is free and confidential, and without obligation.
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages